Docetaxel - paediatric investigation plan
docetaxel
PIPHuman
Key facts
- Invented name
- Taxotere
- Taxotere
- Active Substance
- docetaxel
- Therapeutic area
- Oncology
- Decision number
- P/22/2008
- PIP number
- Docetaxel
- Pharmaceutical form(s)
- Concentrate and solvent for solution for infusion
- Condition(s) / indication(s)
- Nasopharyngeal carcinoma
- Route(s) of administration
- Intravenous use
- Contact for public enquiries
Aventis Pharma SA
E-mail: sylvie.gabriel@sanofi-aventis.com
Country: France
Phone: +33 153774152
Fax: +33 153774133- Decision type
- P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
- Decision date